JP Morgan Initiates Coverage On Odyssey Therapeutics with Overweight Rating, Announces Price Target of $26
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
JP Morgan analyst Brian Cheng initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight rating and announces Price Target of $26.
JP Morgan analyst Brian Cheng initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight rating and announces Price Target of $26.